Remdesivir has not been proven to significantly reduce mortality in all Severe/Critical patients. If CD12 shows a significant reduction (30%+), it will be filling an unmet need.
Also, Rem is an anti-viral while Leronlimab is an immunomodulator. There is a need for both.